StockNews.com Initiates Coverage on Pulmatrix (NASDAQ:PULM)

Equities research analysts at StockNews.com assumed coverage on shares of Pulmatrix (NASDAQ:PULM) in a report issued on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Pulmatrix Stock Performance

Shares of Pulmatrix stock opened at $7.34 on Tuesday. The company’s 50 day moving average price is $2.82 and its 200-day moving average price is $2.30. Pulmatrix has a 52-week low of $1.55 and a 52-week high of $8.44. The stock has a market capitalization of $26.79 million, a price-to-earnings ratio of -2.81 and a beta of 0.99.

About Pulmatrix

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.